Shots:

• Saniona to receive up to $84.6 as milestones along with royalties on sales of the therapies. Boehringer Ingelheim to get an exclusive global right to research- develop- manufacture and commercialize therapeutics- identified under the collaboration
• The focus of the collaboration is to identify new therapies for schizophrenia by utilizing Saniona’s ion channel drug discovery platform
• Saniona will receive funding during the research period and anticipates $0.49M funding- during the first year of collaboration. In 2016- the companies collaborated to develop therapies for schizophrenia- targeting GABA α5 ion channels to treat cognitive impairment with its first program- currently in the preclinical stage

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pinterest